Log in

Relevant bibliographies by topics / 305.5/67/092 b / Journal articles

To see the other types of publications on this topic, follow the link: 305.5/67/092 b.

Journal articles on the topic '305.5/67/092 b'

Author: Grafiati

Published: 25 July 2024

Last updated: 1 August 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic '305.5/67/092 b.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ferrari, Anna C., Yu-Hui Chen, Gary R. Hudes, et al. "E2809: Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in men with rising PSA at high-risk of progression after local prostate cancer (PC) treatment." Journal of Clinical Oncology 34, no. 2_suppl (2016): 9. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.9.

Full text

Abstract:

9 Background: Men with PSA recurrence and fast PSA doubling time (PSADT) are at high risk of progression. While castration effectively decreases PSA and delays metastases, it compromises heath and quality of life without clear survival benefit. E2809 tested whether blocking Akt with MK alone or together with the AR using Bic, would be more effective than Bic alone to suppress AR activity without castration. Methods: 108 PSA-recurrent N0 M0, non-castrate PC patients (pts) with PSADT<12 months (mo) and PSA>2ng/mL; were randomized 1:1 to 11, 4-week (wk) treatment (tx) cycles (cy), up to18cy

APA, Harvard, Vancouver, ISO, and other styles

2

Romero, Samuel, Juan Montoro, Jaime Sanz, et al. "Comparative Study of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation Versus Hematopoietic Stem Cell Transplantation." Blood 126, no. 23 (2015): 4358. http://dx.doi.org/10.1182/blood.v126.23.4358.4358.

Full text

Abstract:

Abstract Introduction. Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication of both solid organ transplantation (SOT) and allogeneic hematopoietic stem cell transplantation (HSCT). However, differences in clinical and biological characteristics between the two procedures are not well established. Methods. We retrospectively evaluated 84 consecutive patients diagnosed of PTLD at a single institution between 1993 and 2014. Results. Sixty-three cases occurred after SOT (25 hepatic, 20 renal, 10 cardiac, 9 pulmonary and 1 double-leg transplant) and 21 after HSCT (1

APA, Harvard, Vancouver, ISO, and other styles

3

Yan, Xiao J., Daniel Kalenscher, Erin Boyle, et al. "Gene Set Enrichment Analysis of Ki-67high CLL Clones Suggests Complex Interactions of B-Cell Receptor Signaling and Normal Cell Interactions in the Disease." Blood 118, no. 21 (2011): 2833. http://dx.doi.org/10.1182/blood.v118.21.2833.2833.

Full text

Abstract:

Abstract Abstract 2833 Introduction: In chronic lymphocytic leukemia (CLL), clonally expanded CD5+ B lymphocytes eventually overwhelm healthy immune cells, hindering normal immune function. To determine mechanisms fueling this expansion, gene expression data were gathered by microarray analysis of cells from CLL patients. Samples were grouped based on Ki-67 expression, an indicator of proliferation. To determine mechanisms correlating with B-cell proliferation and impacting on CLL B-cell biology, microarray profiles were compared using Gene Set Enrichment Analysis (GSEA) [Subramanian A, et al.

APA, Harvard, Vancouver, ISO, and other styles

4

Amisha, Fnu, Sunilkumar Kakadia, and Akash Mukherjee. "Clinical Outcome of Refractory Lymphoma Patients with Non Response to Chimeric Antigen Receptor T Cell Therapy." Blood 138, Supplement 1 (2021): 4823. http://dx.doi.org/10.1182/blood-2021-154356.

Full text

Abstract:

Abstract Background Chimeric antigen receptor T cell (CART) therapy has remarkably improved the outcome of patients (pts) with relapsed refractory B cell non-Hodgkin lymphoma. Anti-CD19 directed CART therapy have shown to yield durable remission in 40%-50% of patients with relapsed refractory (r/r) diffuse large B cell lymphoma (Neelapu et al. NEJM 2017; NCT 02348216). However, pts who had disease progression post CART therapy (non-responders) have poor outcomes. There is paucity of information regarding negative predictors for disease progression and outcome of non-responders post CART therap

APA, Harvard, Vancouver, ISO, and other styles

5

Zahid, Anza, Prema P. Peethambaram, Carrie A. Thompson, et al. "Descriptive evaluation of frequent patient referrals to our cardio-oncology clinic: The Mayo experience." Journal of Clinical Oncology 38, no. 15_suppl (2020): e14018-e14018. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e14018.

Full text

Abstract:

e14018 Background: Cancer survival rates are improving. Therefore, management of cardiovascular complications has now become a crucial clinical concern. Cardio-oncology is the sub-specialty that assists in the overall management of cancer patients in a multi-disciplinary manner. Mayo Clinic cardio-oncology practice was initiated to work closely with our oncology colleagues for early detection of cardiovascular complications in response to cancer-therapy. Majority of the patients visit our cardio-oncology clinic once, we thought it is important to study the group of patients that visited freque

APA, Harvard, Vancouver, ISO, and other styles

6

Davids, Matthew Steven, Andrew Warwick Roberts, John Francis Seymour, et al. "Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)." Journal of Clinical Oncology 35, no. 15_suppl (2017): e19041-e19041. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e19041.

Full text

Abstract:

e19041 Background: VEN is a selective orally bioavailable BCL-2 inhibitor. The dose-escalation Phase 1 study of VEN in 106 patients (pts) with relapsed/refractory NHL reported an ORR of 44%. Most pts had diffuse large B-cell/follicular lymphoma; we report on updated results in pts with less common NHL subtypes. Methods: VEN was administered and continued until progressive disease (PD)/unacceptable toxicity, in dose cohorts ranging from 300–1200 mg. Adverse events (AEs) were assessed by NCI-CTCAE v4.0 and response by 2007 Cheson IWG response criteria, utilizing CT scans beginning at wk 6. Resul

APA, Harvard, Vancouver, ISO, and other styles

7

Moccia, Moccia A., Jane Donaldson, Mukesh Chhanabhai, et al. "The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era." Blood 114, no. 22 (2009): 1554. http://dx.doi.org/10.1182/blood.v114.22.1554.1554.

Full text

Abstract:

Abstract Abstract 1554 Poster Board I-577 Introduction The International Prognostic Factor Project Score (IPS) is the most widely utilized risk stratification index for Hodgkin lymphoma (HL) (Hasenclever, N Engl J Med, 1998). Based on patients treated before 1992, it incorporates 7 adverse risk features (male gender, age ≥45 y, stage IV, hemoglobin <105 g/L, WBC ≥15 × 109/L, lymphocyte count <0.6 × 109/L or <8% of differential, albumin <40 g/L) and predicts for a 5-year freedom-from progression (FFP) ranging from 42-84%.The IPS has not been validated in a more recently treated popu

APA, Harvard, Vancouver, ISO, and other styles

8

Issa, Ghayas C., Hagop M. Kantarjian, C. Cameron Yin, et al. "Prognostic Implications of Pre-Treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia (ALL) Treated with Hyper-CVAD." Blood 126, no. 23 (2015): 4874. http://dx.doi.org/10.1182/blood.v126.23.4874.4874.

Full text

Abstract:

Abstract Background Pretreatment cytogenetic analysis is frequently used to predict response and outcome in hematologic malignancies. Hypodiploidy is associated with a poor prognosis in childhood ALL. Similarly, complex cytogenetics is a known adverse prognostic factor in myeloid malignancies. The impact of hypodiploidy and complex cytogenetics has not been extensively assessed in adult patients with ALL. To address this issue, we have conducted a retrospective analysis of all adult patients with ALL treated with frontline Hyper-CVAD based regimens at our institution. Methods We reviewed 332 a

APA, Harvard, Vancouver, ISO, and other styles

9

Rabaglio, Manuela, Daniel Dietrich, Bernhard Scheibe, et al. "Abstract P4-01-25: Safety analysis after 11 years of follow-up of the randomized phase III trial SAKK22/99: upfront chemotherapy in advanced HER2 positive breast cancer." Cancer Research 83, no. 5_Supplement (2023): P4–01–25—P4–01–25. http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-01-25.

Full text

Abstract:

Abstract Background: The SAKK 22/99 is a phase III randomized clinical trial launched by the Swiss Group for Clinical Cancer Research and the European Institute of Oncology in Milan in 99 for women with HER2-positive advanced breast cancer (ABC). 175 patients were randomized 1:1 from Sept 99 to Jan 2013 to receive first-line trastuzumab (T) alone followed at disease progression by the combination with chemo (Arm A) vs the upfront combination of T and chemo (Arm B). The results were published in 2017 (O. Pagani et al Ann Onc 28: 305–312, 2017). The outcome was similar for sequential T-chemo or

APA, Harvard, Vancouver, ISO, and other styles

10

Квітіньйо Макарена Мартінез, Соріано Федеріко Ґонзало, Яйченко Вірджинія, Стіб Бренда, and Барейро Хуан Пабло. "Predictors of Picture Naming and Picture Categorization in Spanish." East European Journal of Psycholinguistics 6, no. 1 (2019): 6–18. http://dx.doi.org/10.29038/eejpl.2019.6.1.cui.

Full text

Abstract:

The aim of this paper was to identify which psycholinguistic variables are better predictors of performance for healthy participants in a picture naming task and in a picture categorization task. A correlation analysis and a Path analysis were carried out. The correlation analysis showed that naming accuracy and naming latency are significant and positively correlated with lexical frequency and conceptual familiarity variables, whereas they are negatively correlated with H index. Reaction times in the categorization task were negatively correlated with lexical frequency and conceptual familiar

APA, Harvard, Vancouver, ISO, and other styles

11

Lykova, Inna, Ralph Rowe, Glenn Poirier, Henrik Friis, and Kate Helwig. "Mckelveyite group minerals – Part 2: Alicewilsonite-(YCe), Na₂Sr₂YCe(CO₃)₆ ⋅ 3H₂O, a new species." European Journal of Mineralogy 35, no. 1 (2023): 143–55. http://dx.doi.org/10.5194/ejm-35-143-2023.

Full text

Abstract:

Abstract. The new mckelveyite group mineral alicewilsonite-(YCe), ideally Na2Sr2YCe(CO3)6 ⋅ 3H2O, was found at Mont Saint-Hilaire, Quebec, Canada, and subsequently at the Saint-Amable sill, Quebec, Canada, and the Khibiny Massif, Kola Peninsula, Russia. Alicewilsonite-(YCe) crystals are commonly hemimorphic pseudotrigonal and pseudohexagonal and show barrel-shaped, saucer-shaped, spindle-shaped, cone-shaped, columnar, tabular, and platy habits. They are usually up to 2–3 mm in size with some larger crystals reaching 2–3 cm. The crystals often form stacked or parallel growth aggregates and rose

APA, Harvard, Vancouver, ISO, and other styles

12

Varettoni, Marzia, Luca Arcaini, Silvia Zibellini, et al. "Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenström Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms." Blood 120, no. 21 (2012): 2667. http://dx.doi.org/10.1182/blood.v120.21.2667.2667.

Full text

Abstract:

Abstract Abstract 2667 Waldenström Macroglobulinemia (WM) is a B-cell lymphoproliferative disorder characterized by bone marrow infiltration by lymphoplasmacytic lymphoma associated with a monoclonal component of IgM type in the serum. WM is often preceded by an IgM monoclonal gammopathy of undetermined significance (IgM-MGUS). The cumulative probability of progression of IgM-MGUS to WM or to other lymphoproliferative disorders is approximately 1.5% per year. Other mature B-cell neoplasms such as splenic marginal zone lymphoma (SMZL) and B-cell chronic lymphoproliferative disorders (B-CLPD) c

APA, Harvard, Vancouver, ISO, and other styles

13

Castillo, Jorge, Brady Beltran, Jaime Collins, et al. "Clinicopathologic Characteristics of HIV-Associated Peripheral T-Cell Lymphoma." Blood 114, no. 22 (2009): 3924. http://dx.doi.org/10.1182/blood.v114.22.3924.3924.

Full text

Abstract:

Abstract Abstract 3924 Poster Board III-860 Introduction The incidence of lymphomas is increased in HIV-infected individuals. Most of the cases are B-cell subtypes of non-Hodgkin lymphoma. Although the incidence of mature or peripheral T-cell lymphomas (PTCL) seems to be increased in HIV-positive cases, clinicopathological data is lacking. The objective of this study is to describe the characteristics of non-cutaneous PTCL in HIV-infected individuals and identify potential prognostic factors. Methods Institutions within and outside of the United States were invited to submit original data on c

APA, Harvard, Vancouver, ISO, and other styles

14

Yilmaz, Musa, Hagop M. Kantarjian, Jorge Cortes, et al. "Results of Intensive Chemotherapy in 434 Adult Patients (pts) with Philadelphia-Negative Acute Lymphoblastic Leukemia (ALL): Predictive Prognostic Model for Survival." Blood 126, no. 23 (2015): 3722. http://dx.doi.org/10.1182/blood.v126.23.3722.3722.

Full text

Abstract:

Abstract Introduction: Older age, poor performance status, diminished organ function and adverse genetic features are poor prognostic factors in treatment of ALL. Our goal is to develop prognostic models predicting complete response (CR), death in CR, 2-month mortality and survival in adult pts with ALL, which would be used to assist pts and oncologists to establish expectations with intensive chemotherapy. Methods: A total of 434 pts with ALL treated with intensive chemotherapy between 2000 and 2015 were analyzed. Frontline treatments included hyperCVAD alone (n=152) or in combination with ri

APA, Harvard, Vancouver, ISO, and other styles

15

Scheid, Christof, Pieter Sonneveld, Ingo Schmidt-Wolf, et al. "Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma." Blood 116, no. 21 (2010): 2396. http://dx.doi.org/10.1182/blood.v116.21.2396.2396.

Full text

Abstract:

Abstract Abstract 2396 Introduction: Renal impairment is a frequent complication in patients with multiple myeloma (MM) and is correlated with an inferior prognosis. Bortezomib can be applied independently of renal function and has been shown to improve response and overall survival in patients with relapsed MM. We wanted to investigate the role of renal impairment in the context of a large randomized study comparing a bortezomib-containing induction regimen (PAD) with standard VAD followed by HDM and maintenance with either thalidomide or bortezomib. Methods: Patients were randomly assigned t

APA, Harvard, Vancouver, ISO, and other styles

16

Schönland, Stefan, Ute Hegenbart, Christoph Kimmich, et al. "Detection and Characterization of Plasma Cell and B Cell Clones in Patients with Systemic Light Chain Amyloidosis Using Flow Cytometry." Blood 124, no. 21 (2014): 2068. http://dx.doi.org/10.1182/blood.v124.21.2068.2068.

Full text

Abstract:

Abstract Introduction: AL amyloidosis is a rare and life-threatening protein-deposition disorder caused by a small B cell (mostly plasma cell) clone which produces amyloidogenic light chains. The goal of therapy is to target this clone and halt the uncontrolled release of free light chain, which might subsequently lead to improvement of organ function. In routine diagnostic some of these B cell clones are missed as they might be extremely small. However, specific treatment can only be applied if the clone is well characterized. Hardly any data on the characteristics of these cells using flow c

APA, Harvard, Vancouver, ISO, and other styles

17

Saxton, Claire, Kirstin Fearnley, Maria B. Gonzalo, and Cynthia Schwartz. "Abstract P3-17-01: Metastatic breast cancer caregiver participation in a psychoeducational cancer support program: Results from the frankly speaking about cancer: Metastatic breast cancer evidence-based educational workshops." Cancer Research 82, no. 4_Supplement (2022): P3–17–01—P3–17–01. http://dx.doi.org/10.1158/1538-7445.sabcs21-p3-17-01.

Full text

Abstract:

Abstract Background: Education about metastatic breast cancer can help caregivers by providing tools to deal with the psychosocial effects of the disease. This analysis explores metastatic breast cancer caregivers’ experiences related to participation in Cancer Support Community’s national evidence-based educational program, Frankly Speaking About Cancer: Metastatic Breast Cancer. This comprehensive psychosocial education program, created for people diagnosed with metastatic breast cancer and their caregivers, provides information about current treatments, side-effect management, and social an

APA, Harvard, Vancouver, ISO, and other styles

18

Andreica, I., I. Roman, X. Baraliakos, U. Kiltz, and J. Braun. "AB1188 SARS-CoV-2 VACCINATION WILLINGNESS AND PREDICTORS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES (CIRD) AND WITHOUT CIRD." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1709.1–1709. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5261.

Full text

Abstract:

BackgroundRecent surveys in chronic inflammatory rheumatic diseases (CIRD) showed a high degree of vaccine hesitancy. Current knowledge about patients’ attitudes towards vaccination against SARS-CoV-2 is limited.ObjectivesTo assess the willingness of CIRD patients to be vaccinated against SARS-CoV-2 and to identify influencing factors compared to non-CIRD patients.MethodsIn this cross-sectional study, two cohorts of consecutively in parallel recruited patients with and without CIRD presenting to our tertiary hospital answered questions of a structured interview to assess vaccination willingnes

APA, Harvard, Vancouver, ISO, and other styles

19

Seymour, John F., Chan Yoon Cheah, Ricardo Parrondo, et al. "First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)." Blood 142, Supplement 1 (2023): 4401. http://dx.doi.org/10.1182/blood-2023-180109.

Full text

Abstract:

Introduction: BTK inhibitors (BTKis) are approved for chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL). Disease that progresses on BTKis often has BTK mutations that lead to treatment (tx) resistance; novel BTK-targeting agents that overcome BTKi resistance are needed. BGB-16673 is a heterobifunctional small molecule that binds to BTK and E3 ligase, resulting in BTK degradation via ubiquitination. In preclinical models, BGB-16673 degraded wild-type (WT) BTK and known covalent and noncovalent BTKi-resistant muta

APA, Harvard, Vancouver, ISO, and other styles

20

Call, Justin, Muralidhar Beeram, Alexander I. Spira, et al. "Abstract PO2-04-13: TWT-203: PHASE 1b/2 STUDY OF CFI-402257 AS MONOTHERAPY IN ADVANCED SOLID TUMORS AND IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER AFTER PROGRESSION ON PRIOR CDK4/6 INHIBITORS AND ENDOCRINE THERAPY." Cancer Research 84, no. 9_Supplement (2024): PO2–04–13—PO2–04–13. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-04-13.

Full text

Abstract:

Abstract Background: TTK (Threonine Tyrosine Kinase also known as Monopolar spindle 1), is a dual-specificity serine-threonine kinase critical for anaphase promoting complex inhibition at the spindle assembly checkpoint and is required for chromosome alignment and error correction. TTK inhibition results in premature mitosis exiting with unattached chromosomes potentially leading to aneuploidy and cell death. High TTK tumor levels correlate with worse prognosis and contribute to the survival and proliferation of aneuploid cells. CFI-402257, a potent and selective inhibitor of TTK, inhibits the

APA, Harvard, Vancouver, ISO, and other styles

21

Baliakas, Panagiotis, Theodoros Moysiadis, Anastasia Hadzidimitriou, et al. "Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors." Blood 128, no. 22 (2016): 3199. http://dx.doi.org/10.1182/blood.v128.22.3199.3199.

Full text

Abstract:

Abstract The classification of CLL patients according to the somatic hypermutation status (SHM) of the immunoglobulin heavy variable (IGHV) genes, namely mutated (M-CLL) versus unmutated (U-CLL), reflects fundamental differences in disease biology and clinical course. Realizing this, here we followed a compartmentalized approach and addressed the issue of prognostication separately for M-CLL and U-CLL. In a multi-institutional cohort of 2366 patients [M-CLL, n=1364 (58%); U-CLL, n=1002 (42%)] consolidated within ERIC, the European Initiative in CLL, we assessed the clinical impact of 'traditio

APA, Harvard, Vancouver, ISO, and other styles

22

George III, Qiuhong Zhao, Timothy Voorhees, et al. "Association between post-CART terminal complement complex (TCC) levels and clinically significant immune effector cell–associated neurotoxicity syndrome (ICANS)." Journal of Clinical Oncology 42, no. 16_suppl (2024): 7036. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.7036.

Full text

Abstract:

7036 Background: The cornerstone of ICANS pathogenesis is endothelial dysfunction leading to blood-brain barrier disruption driven by inflammatory cytokines. Endothelial dysfunction is often associated with complement activation as in thrombotic microangiopathy, but the association between complement and ICANS has not yet been investigated. Herein, we describe the association between TCC levels (sC5b-9) and ICANS after CART. Methods: We retrospectively included 42 patients (pts) with B-cell non-Hodgkin lymphoma treated with axi-cel or brexu-cel from 03/2022 - 09/2023 at Ohio State University w

APA, Harvard, Vancouver, ISO, and other styles

23

Farooq, Umar, Matthew J. Maurer, Stephen M. Ansell, et al. "Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy." Blood 126, no. 23 (2015): 2683. http://dx.doi.org/10.1182/blood.v126.23.2683.2683.

Full text

Abstract:

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is curable for the majority of patients treated with anthracycline based immunochemotherapy (IC). However, up to 40% of patients will relapse or require retreatment of DLBCL and outcomes are poor in this setting. Here we examine the incidence, treatment patterns and outcomes of relapsed DLBCL in the R-CHOP era. Methods: Patients were prospectively enrolled in the University of Iowa / Mayo Clinic SPORE Molecular Epidemiology Resource (MER) within 9 months of diagnosis and followed for relapse, retreatment, and death. Clinical management

APA, Harvard, Vancouver, ISO, and other styles

24

Retiere, Christelle, Catherine Willem, Thierry Guillaume, et al. "Post-Transplant Cyclophosphamide (PTCY) Vs Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) in Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Immune Reconstitution." Blood 126, no. 23 (2015): 1955. http://dx.doi.org/10.1182/blood.v126.23.1955.1955.

Full text

Abstract:

Abstract Introduction: The influence of PTCY on early immune reconstitution after allo-SCT has been poorly studied so far, especially in comparison to standard use of ATG as GVHD prophylaxis. Patients and Methods: A prospective study was conducted at the CHU of Nantes with the aim to compare early immune recovery between patients receiving PTCY or ATG as GVHD prophylaxis after a RIC allo-SCT. Secondary objectives were to study the impact of 1 vs 2 days of PTCY (CY1 vs CY2) or ATG (A1 vs A2), and of fludarabine (Flu) vs clofarabine (Clo) as part of the RIC regimen. As such, 3 RIC regimens were

APA, Harvard, Vancouver, ISO, and other styles

25

Song, Alexander, Ron Ng, John Heller, et al. "251 Factors evaluated as predictors of exceptional response to PD-1 inhibitors in patients with head and neck squamous cell cancer." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A272. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0251.

Full text

Abstract:

BackgroundImmunotherapy has recently emerged as an alternative to traditional chemotherapy in the management of recurrent or metastatic head and neck squamous cell cancer (HNSCC). PD-1 inhibitors were approved for HNSCC in 2016 with ORR of 13–18% and CR of 4%.1, 2 Current research focuses on identifying predictors of response for better patient selection. We present HNSCC patients with exceptional response to PD-1 inhibitors in an attempt to highlight biomarkers that correlated with their remarkable response.MethodsWe analyzed all cases of HNSCC treated with single agent PD-1 inhibitors in the

APA, Harvard, Vancouver, ISO, and other styles

26

Swic, Sebastian J., Alexander G. T. MacPhail, Chinmay B. Dalal, et al. "Prognostic Factors and Outcomes in Allogeneic Hematopoietic Stem Cell Transplant Vs. Non-Transplant Chronic Lymphocytic Leukemia (CLL) Patients: A Comparative Analysis with the Leukemia/BMT Program of British Columbia (BC) and the BC Provincial CLL Database." Blood 124, no. 21 (2014): 2549. http://dx.doi.org/10.1182/blood.v124.21.2549.2549.

Full text

Abstract:

Abstract Background: Chronic Lymphocytic Leukemia (CLL) patients (pts) have significant (sig) heterogeneity; survival ranges from decades to <5 years (yrs). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is promising treatment (tx) for high-risk pts. Ideally, predictive (pred) tools would allow clinicians to recognize such pts early, permitting transplant performance to maximize benefit and minimize procedure associated risk. Factors with significant (sig) pred capacity are not, however, entirely clarified. Moreover, limited studies compare CLL pts who have/have not received

APA, Harvard, Vancouver, ISO, and other styles

27

Donato, Eva Ma, Rafa Andreu, Aurelio Lopez, et al. "A Retrospective Population-Based Study of a Series of 307 Treatment-naïve Patients with Chronic Lymphocytic Leukemia (CLL): Study of the Clinical Features and Efficacy of First-Line Therapy." Blood 116, no. 21 (2010): 2452. http://dx.doi.org/10.1182/blood.v116.21.2452.2452.

Full text

Abstract:

Abstract Abstract 2452 Background. Clinical trials have shown an improved response rate and progression free survival (PFS) among the different treatment options used in the last two decades, specially with rituximab in combination with fludarabine and cyclophosphamide. We wished to analyze, in an unselected community based population, the clinical characteristics and efficacy of first line therapy with several treatment options used throughout a ten-year period. Patients and methods. We included 307 patients diagnosed of CLL and requiring first-line treatment between January 2000 and Septembe

APA, Harvard, Vancouver, ISO, and other styles

28

Aljawai, Yosra, Serena McDiarmid, Joseph Cappuccio, et al. "A Case-Control Epidemiological Study Of Waldenstrom Macroglobulinemia." Blood 122, no. 21 (2013): 1713. http://dx.doi.org/10.1182/blood.v122.21.1713.1713.

Full text

Abstract:

Abstract Introduction Waldenstrom Macroglobulinemia (WM) is a distinct lymphoplasmacytic disorder characterized by bone marrow (BM) infiltration and IgM secretion. The etiology remains unknown, but a role for genetic and immune-related factors in the pathogenesis is suspected. To date, few etiologic studies have focused specifically on WM. Therefore, we initiated a large case-control study of WM to evaluate a comprehensive panel of potential risk factors. Here we describe the study design and report initial findings in the enrolled WM patients. Methods Patients are recruited into the study thr

APA, Harvard, Vancouver, ISO, and other styles

29

Murillo, Ilda, Marcio M. Andrade, Anel Montes, Jose M. Grasa, and Pilar Giraldo. "Are IgM Hevylite® Immunoglobulin Heavy Chain/Light Chain Analysis a Useful Tool to Differentiate IgM MGUS From Waldenström Macroglobulinemia?" Blood 120, no. 21 (2012): 5097. http://dx.doi.org/10.1182/blood.v120.21.5097.5097.

Full text

Abstract:

Abstract Abstract 5097 Background: Monoclonal IgM is the biomarker that characterize to Waldenstrom's macroglobulinemia (WM), a rare low grade B-cell lymphoma derived of the lymphoplasmacytic cell, even serum IgM component also is presented in MGUS. Recently new determinations of heavy chain/light chain immunoglobulins pairs (HLC) have been developed as biomarkers to apply to every day clinical practice. The diagnostic and prognostic potential of these biomarkers is under investigation. The aim of this study is to present our experience in the use of free light chain assay (sFLC) and HLC as bi

APA, Harvard, Vancouver, ISO, and other styles

30

Narayanan, Bhagavathi A., Cronstein Bruce, Mediero Aranzazu,, and Amitabha Mazumder. "Differential Activity of Brain Derived Neurotrophic Factor (BDNF) and RANKL in Promoting Osteoclast Activity in Multiple Myeloma Patients with or without Bone Disease." Blood 124, no. 21 (2014): 2058. http://dx.doi.org/10.1182/blood.v124.21.2058.2058.

Full text

Abstract:

Abstract Purpose: Brain derived neurotrophic factor (BDNF) which plays an important role in the development of neuronal cells, has a high affinity receptor TrkB and expressed in malignant plasma cells and osteoblasts.Recent reports onage related changes in human serum levels of BDNF drew our attention to further investigate whether soluble BDNF from myeloma cells contributes for the bone related osteolytic activities in MM patients. To answer this question, we analyzed samples from three group of MM patients; (a) bone related early stage, (b) late stage and (c) non-bone related early stage MM

APA, Harvard, Vancouver, ISO, and other styles

31

Ionescu, Filip, Nwabundo Anusim, Eva Ma, et al. "Inferior Vena Cava Filter Retrieval Trends: A Single Center Experience." Blood 134, Supplement_1 (2019): 4690. http://dx.doi.org/10.1182/blood-2019-129366.

Full text

Abstract:

Background: Inferior vena cava (IVC) filters are indicated in patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) who either have contraindications to or have failed anticoagulation (AC). Given rising concerns about their safety and efficacy, the FDA has issued a communication urging clinicians to remove filters (optimally, within 90 days post-implantation). According to national data retrieval rates remain low. Our study aimed to assess IVC filter retrieval rates and factors that influence retrieval. Methods: This is a single center, retrospective cohort study of patients who

APA, Harvard, Vancouver, ISO, and other styles

32

Wang, Wenrui. "The Ways that Digital Technologies Inform Visitor's Engagement with Cultural Heritage Sites: Informal Learning in the Digital Era." GATR Global Journal of Business Social Sciences Review 10, no. 4 (2022): 237–48. http://dx.doi.org/10.35609/gjbssr.2022.10.4(3).

Full text

Abstract:

1. Alivizatou, M. (2019). Digital intangible heritage: Inventories, virtual learning and participation. Heritage & Society, 12(2–3), 116–135. 2. Billett, S. (2009). Conceptualizing learning experiences: Contributions and mediations of the social, personal, and brute. Mind, Culture, and Activity, 16(1), 32–47. 3. Bonilla, C. M. (2014). Racial Counternarratives and L atina Epistemologies in Relational Organizing. Anthropology & Education Quarterly, 45(4), 391–408. 4. Britain, T. (2007). How We Are: Photographing Britain. 5. Brodie, R. J., Hollebeek, L. D., Jurić, B., & Ilić, A. (2011

APA, Harvard, Vancouver, ISO, and other styles

33

Kumar, Priya, Todd E. Defor, Claudio Brunstein, et al. "Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Acute Lymphocytic Leukemia (ALL) in 126 Adults: Impact of Donor Source on Leukemia Free Survival (LFS)." Blood 106, no. 11 (2005): 2064. http://dx.doi.org/10.1182/blood.v106.11.2064.2064.

Full text

Abstract:

Abstract White blood cell (WBC) count and specific cytogenetic abnormalities at diagnosis, patient age and disease status at HSCT have previously been identified as risk factors associated with LFS in patients with ALL. As the use of umbilical cord blood (UCB) is relatively new, particularly for adults, we sought to evaluate the relative impact of donor source. In this single center study, 126 adults aged 18–61 (median 31) years (yrs) underwent myeloablative conditioning (cyclophosphamide 120 mg/kg and total body irradiation 1320–1375 cGy based regimen in 92%) followed by allogeneic HSCT. Stem

APA, Harvard, Vancouver, ISO, and other styles

34

Morel, J., L. Dagna, B. Joven-Ibáñez, et al. "AB0899 A 24-month Prospective Psoriatic Arthritis Observational Study of Persistence of Treatment (PRO-SPIRIT) - Interim Analysis of Baseline Characteristics." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 1578.1–1578. http://dx.doi.org/10.1136/annrheumdis-2022-eular.1984.

Full text

Abstract:

BackgroundIxekizumab (ixe), a highly selective interleukin (IL)-17A monoclonal antibody, has been approved for treatment of psoriatic arthritis (PsA). However, there is limited real-world evidence (RWE) available for ixe. PRO-SPIRIT is the first large-sample prospective observational study to provide RWE for ixe in patients (pts) with PsA.ObjectivesPRO-SPIRIT’s primary objective is to describe treatment persistence at 24 months (M) among pts with PsA who initiate or switch to a new biologic Disease Modifying Arthritis Rheumatic Drugs (bDMARDs) or targeted synthetic (tsDMARDs), including ixe. T

APA, Harvard, Vancouver, ISO, and other styles

35

Dewi, Melina Surya, and Yufiarti. "Play-based Learning Activities for Creativity in Children's Dance Movements." JPUD - Jurnal Pendidikan Usia Dini 15, no. 1 (2021): 101–20. http://dx.doi.org/10.21009/jpud.151.06.

Full text

Abstract:

Play-based learning activities are important programs throughout the world of children's education. Through play, children learn creatively and constructively. This study aims to solve the problem of creativity in early-childhood dance movements with the hope that there will be an increase in aspects of fluency, flexibility and elaboration through play activities related to educational dance. This action research uses an action research method which is carried out in three cycles. The subjects in this study were 19 children aged 5-6 years in Kindergarten in Central Jakarta. Data collection was

APA, Harvard, Vancouver, ISO, and other styles

36

Cortivo, Liliane Dal, Mathilde Bahuaud, Marie Noelle Lacassagne, Vincent Monchois, Cecile Ducasse, and Marina Cavazzana-Calvo. "Anti CMV Immunotherapy with Donor Antigen Specific Lymphocytes Selected with GMP HLA Class 1 Tetramer Reagents." Blood 114, no. 22 (2009): 4492. http://dx.doi.org/10.1182/blood.v114.22.4492.4492.

Full text

Abstract:

Abstract Abstract 4492 Patients undergoing allogeneic haematopoietic stem cell transplants frequently develop infections that are responsible for a high rate of morbidity and mortality during first 6 months post transplantation. The occurrence of CMV infection might reach 70% to 80% of transplanted patients; this rate is increased in HSC transplantations conditioned by in vivo and/or in vitro immunosuppressive treatment. Prophylactic treatment of CMV infection by ganciclovir or foscarnet, though proven to be efficient, faces complications such as myelotoxicity, nephrotoxicity and/or the develo

APA, Harvard, Vancouver, ISO, and other styles

37

Sehn, Laurie H., Angela Giovanna Congiu, Dominic J. Culligan, et al. "No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study." Blood 132, Supplement 1 (2018): 783. http://dx.doi.org/10.1182/blood-2018-99-116845.

Full text

Abstract:

Abstract Introduction: Standard of care for previously untreated patients (pts) with diffuse large B-cell lymphoma (DLBCL) is rituximab (R) plus 6-8 cycles of CHOP (R-CHOP). While the RICOVER trial (Pfreundschuh et al. Lancet Oncol 2008) showed no benefit of 6 versus 8 cycles of R-CHOP administered at 2-weekly intervals, this has not been assessed with the standard 3-weekly regimen, and many centers continue to administer 8 cycles. GOYA (NCT01287741) was an open-label, randomized, Phase III study of the efficacy and safety of R-CHOP versus obinutuzumab (GA101; G) plus CHOP in previously untrea

APA, Harvard, Vancouver, ISO, and other styles

38

Burns, David, Katherine Clesham, Joanna Haughton, et al. "Outcomes With Rituximab Monotherapy Versus R-CHOP In Post-Transplant Lymphoproliferative Disease Arising After Solid Organ Transplant: A Multicentre UK Study." Blood 122, no. 21 (2013): 3043. http://dx.doi.org/10.1182/blood.v122.21.3043.3043.

Full text

Abstract:

Abstract Post-transplant lymphoproliferative disease (PTLD) remains an important complication of solid organ transplantation. For B-cell PTLD, current first line therapies are Rituximab monotherapy (R-Mono) or R-CHOP. However, optimal selection of initial treatment is challenging due to concerns about the relative efficacy and toxicity of these modalities, and because of uncertainty about the prognostic value of baseline factors. This retrospective study identified 72 biopsy-proven cases of PTLD, diagnosed between 2000 and 2012, from 4 UK centres. These included 34 liver, 32 renal and 6 cardio

APA, Harvard, Vancouver, ISO, and other styles

39

Abaza, Yasmin, Hagop M. Kantarjian, Gautam Borthakur, et al. "An Open-Label, Phase I Study of Dasatinib in Combination with Decitabine in Patients (Pts) with Accelerated or Blastic Phase Chronic Myeloid Leukemia (CML)." Blood 128, no. 22 (2016): 5433. http://dx.doi.org/10.1182/blood.v128.22.5433.5433.

Full text

Abstract:

Abstract Background: Current treatment for advanced phase CML remains unsatisfactory. Dasatinib induces major cytogenetic response (MCyR) in 31% and 37% of pts with imatinib-resistant or -intolerant accelerated (AP) and blast phase (BP), respectively (Cortes 2007). Hypermethylation is associated with disease progression in CML. In pts with imatinib-refractory CML-AP and CML-BP, low dose decitabine induced MCyR in 12% and 17% of pts, respectively, with similar rates achieved combining decitabine with imatinib (Issa 2005, Oki 2007). The reported synergy between imatinib and decitabine depends up

APA, Harvard, Vancouver, ISO, and other styles

40

Pieri, Lisa, Giada Rotunno, Francesca Gesullo, et al. "Prognotic Impact of Mutations in Systemic Mastocytosis." Blood 128, no. 22 (2016): 1953. http://dx.doi.org/10.1182/blood.v128.22.1953.1953.

Full text

Abstract:

Abstract Introduction: Systemic mastocytosis (SM) is an heterogeneous myeloproliferative neoplasm characterized by uncontrolled growth of cKIT mutated clonal mast cells, with clinical manifestations ranging from indolent forms (ISM) with only skin lesions and/or anaphylactic shock to smouldering SM (SSM) with evidence of organ involvement to aggressive forms (ASM) with extensive organ damage. SM with an associated hematological neoplasm (SM-AHN) is a subtype with adverse prognosis possibly related to the associated neoplasm rather than SM. Recent data indicate that mutations in genes associate

APA, Harvard, Vancouver, ISO, and other styles

41

M, Luis Villela, Ana Ramirez-Ibarguen, Brady E. Beltrán та ін. "Assessment of Different Biological Variables (Serum Albumin, β-2-Microglobulin, Lymphocyte/Monocyte ratio, Neutrophil/Lymphocyte ratio, Platelet/Lymphocyte ratio) in a Retrospective Cohort of 525 Diffuse Large B-Cell Lymphomas As Predictor Factor(s) for Overall Survival". Blood 134, Supplement_1 (2019): 1613. http://dx.doi.org/10.1182/blood-2019-123841.

Full text

Abstract:

Introduction. Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphomas (NHL). The use of chemoimmunotherapy (R-CHOP) in DLBCL has improved Overall Survival (OS). However, there are among 45-55% of patients who will die due to relapse, progression (refractoriness) or toxicity to treatment. Genomic classifications are difficult to use in clinical practice, especially in lain America, due to the need of trained personnel and cost. So, we continue using the International Prognostic Index (IPI) and its variations (e.g. revised-IPI, NCCN-IPI) for prognostic purposes.

APA, Harvard, Vancouver, ISO, and other styles

42

Fix, Samantha, Marie-Andrée Forget, Donastas Sakellariou-Thompson та ін. "172 Overcoming immunosuppressive TGF-β signaling in human ovarian cancer-derived tumor infiltrating lymphocytes via non-viral CRISPR engineering". Journal for ImmunoTherapy of Cancer 9, Suppl 2 (2021): A183—A184. http://dx.doi.org/10.1136/jitc-2021-sitc2021.172.

Full text

Abstract:

BackgroundOur ongoing clinical trial for the treatment of melanoma with TGF-β-resistant tumor-infiltrating lymphocytes (TIL) [TGF-β dominant negative receptor 2 (TGFβDNR2) transduced-TIL] has yielded long-term responses in checkpoint refractory patients (NCT01955460). Building on this success, we sought to extend the impact of TGF-β–resistant TIL therapy to additional cancers while optimizing a non-viral alternative to transduction with a TGFβDNR2. Ovarian cancer (OvCa), which is characterized by an abundance of TGF-β, a dysfunctional immune infiltrate, and a paucity of novel treatment options

APA, Harvard, Vancouver, ISO, and other styles

43

Corcione, Silvia, Cecilia Grosso, Ernesta Audisio, et al. "Pharmacogenetics and Pharmacokinetics of Posaconazole in Patients with Acute Myeloid Leukemia: Useful Tools for Antifungal Stewardship." Blood 142, Supplement 1 (2023): 5849. http://dx.doi.org/10.1182/blood-2023-190034.

Full text

Abstract:

DISCUSSION INTRODUCTION Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy is usually recommended [1]. Few studies described the clinical impact of suboptimal posaconazole plasma concentrations during prophylaxis, which may be associated with a higher risk of invasive fungal infections (IFI) and a strong impact on clinical outcome [2]. ENDPOINT: The primary endpoint of this study was to evaluate weekly posaconazole Cthrough plasma concentration in AML patients treated with induction chemotherapy. Since polymorphisms of genes

APA, Harvard, Vancouver, ISO, and other styles

44

Bishton, Mark, Pier Luigi Zinzani, Scott Marshall, et al. "Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study." Blood 134, Supplement_1 (2019): 4135. http://dx.doi.org/10.1182/blood-2019-121957.

Full text

Abstract:

Background: In February 2017, CT-P10 became the first rituximab biosimilar to be approved in Europe for treatment of rheumatic diseases and specific blood cancers including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukaemia (CLL). More recently, CT-P10 was approved in the US for NHL. Although the recommended rituximab administration protocol is a slow initial infusion rate with gradual up-titration, rapid infusion protocols are used widely in patients with no serious complications from their first infusion. There are limited data on the safety of rapidly infused CT-P10. Aims: To ev

APA, Harvard, Vancouver, ISO, and other styles

45

Novi Sekar Sari, Ririn Tri Ratnasari, Ismah Osman, and Ega Rusanti. "Materialism and Environmental Knowledge as a Mediator for Relationships between Religiosity and Ethical Consumption." Jurnal Ekonomi Syariah Teori dan Terapan 10, no. 5 (2023): 467–81. http://dx.doi.org/10.20473/vol10iss20235pp467-481.

Full text

Abstract:

ABSTRACTOn a global and regional scale, Indonesia has one of the least environmentally sustainable economies in the Asia-Pacific region. Consumption is one of the key factors contributing to environmental degradation. By using materialism and environmental knowledge as mediators, this study aimed to understand how religiosity affects ethical consumption. This research used quantitative methods with structural equation modeling (SEM) analysis techniques based on partial least squares (PLS). The data came from a questionnaire distributed online. 153 valid questionnaires were selected for analysi

APA, Harvard, Vancouver, ISO, and other styles

46

MacMillan, Margaret L., Marie Robin, Andrew C. Harris, et al. "A Refined Clinical Risk Score at Onset of Treatment for Acute Gvhd That Predicts Response to Initial Therapy, Survival and Transplant-Related Mortality." Blood 124, no. 21 (2014): 188. http://dx.doi.org/10.1182/blood.v124.21.188.188.

Full text

Abstract:

Abstract Corticosteroids are the standard initial therapy for acute graft-versus-host disease (aGVHD) but are effective in only half of the cases. Methods to identify patients who are unlikely to respond to conventional initial therapy and who warrant alternative, more effective initial therapy are needed. The Minnesota (MN) group recently defined high-risk (HR)-aGVHD at onset by a novel acute GVHD risk score (Br J Haem 157(6):732,2012). Patients with HR-aGVHD were less likely to respond to steroid therapy and had a 2-fold increased risk of treatment-related (non-relapse) mortality (TRM) compa

APA, Harvard, Vancouver, ISO, and other styles

47

Wang, Michael, Javier Munoz, Andre H. Goy, et al. "One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma." Blood 136, Supplement 1 (2020): 20–22. http://dx.doi.org/10.1182/blood-2020-136382.

Full text

Abstract:

Background: KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is currently being evaluated in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who received 1 - 5 prior therapies (including a Bruton tyrosine kinase inhibitor) in the Phase 2, registrational, multicenter ZUMA-2 study. With a median follow-up of 12.3 months, we previously reported an objective response rate (ORR) of 93% (67% complete response [CR] rate) with KTE-X19 treatment in the 60 efficacy-evaluable patients in ZUMA-2 (Wang et al. N Engl J Med. 2020;382:1331). Here, we present

APA, Harvard, Vancouver, ISO, and other styles

48

Warmansyah, Jhoni, Elis Komalasari, Eliza Febriani, Gusmiati, and Amalina. "Factors Affecting Teacher Readiness for Online Learning (TROL) in Early Childhood Education: TISE and TPACK." JPUD - Jurnal Pendidikan Usia Dini 16, no. 1 (2022): 32–51. http://dx.doi.org/10.21009/jpud.161.03.

Full text

Abstract:

This study aims to find empirical information about the effect of Technological Pedagogical Content Knowledge (TPACK), and Technology Integration Self Efficacy (TISE) on Teacher Readiness for Online Learning (TROL). This study uses a quantitative survey method with path analysis techniques. This study measures the readiness of kindergarten teachers in distance learning in Tanah Datar Regency, West Sumatra Province, Indonesia with a sampling technique using simple random sampling involving 105 teachers. Empirical findings reveal that; 1) there is a direct positive effect of Technology Integrati

APA, Harvard, Vancouver, ISO, and other styles

49

Kohls-Santos, Pricila, and Marília Costa Morosini. "Trilha para internacionalização em casa: Brasil-Colômbia em espaços não formais (Trail to internationalization at home: Brazil-Colombia in non-formal spaces)." Revista Eletrônica de Educação 15 (November 30, 2021): e4884048. http://dx.doi.org/10.14244/198271994884.

Full text

Abstract:

e4884048One of the impacts of the pandemic caused by Covid-19 is the decrease in internationalization via academic mobility and the need to consolidate other forms of internationalization, such as “internationalization at home” – IaH. In this context, this article discusses an internationalization experience between Brazil and Colombia, with the aim of offering subsidies to the concept of internationalization at home. To reach the proposed objective, qualitative research was carried out, through a case study, in the discipline of Education in Non-Formal Spaces, in a community university. The e

APA, Harvard, Vancouver, ISO, and other styles

50

Imber, Brandon S., Miguel-Angel Perales, Jessica Flynn, et al. "Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas." Blood 136, Supplement 1 (2020): 1–2. http://dx.doi.org/10.1182/blood-2020-140991.

Full text

Abstract:

Background: CD19-targeted chimeric antigen receptor T-cell therapies (CART) have remarkable overall response rates (ORR) for relapsed/refractory diffuse large B cell lymphoma (DLBCL). Given the time interval between apheresis (Aph) and product delivery, bridging interventions (BI) have been used to provide disease control prior to CART infusion. Real world data suggests about half of patients (pts) require BI such as systemic therapies (ST), radiotherapy (RT) or combined modality therapy (CMT). Early data has associated BI with poorer prognosis however this remains unclear. While no BI strateg

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!